ArticleACS sensors2025
Self-referenced Digital Spectral Chromatic Local Surface Plasmon Resonance in Ultrasensitive Severe Sepsis Interleukin-6 Detection.
Article in ACS sensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MCC950-Loaded M12-Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis-Induced Muscle Atrophy.Journal of cachexia, sarcopenia and muscle · 2026Article
- Localized surface plasmon resonance-based point-of-care testing for pediatric sepsis.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical monitoring of cytokines, such as interleukin-6 (IL-6), enables a timely diagnosis and can significantly improve patient prognosis. In this study, we developed a rapid, label-free, ultrasensitive, and low matrix-effect method called chromatic digital nanoplasmon-metry (cDiNM) to detect IL-6 in human blood plasma. Utilizing a multiple filter configuration, two nonadjacent specific transmission wavelength bands are extracted. One is centered within the full-width-at-half-maximum (fwhm) range where the local surface plasmon resonance (LSPR) response of the 80 nm gold nanoparticles (AuNPs) is strongest, while the other band is narrowed and blue-shifted from the peak to a region with minor intensity change. Scattering images of AuNPs passing through these two bands are then captured simultaneously and independently via the red and green channels of a color scientific complementary metal-oxide-semiconductor (sCMOS) camera. This configuration allows every AuNPs' spectral chromatic image contrast to be a self-referenced subtractive analysis LSPR and facilitates evaluation of their changes induced by the IL-6 binding across numerous individual AuNPs. This method achieves IL-6 detection in blood plasma within 45 min, requiring only 0.5 mL of a 10-fold diluted, label-free sample, with a limit of detection and quantification (LOD and LOQ) of less than 19.2 and 87.8 fg/mL, respectively, and a recovery rate of 96%. In summary, cDiNM provides rapid and accurate IL-6 monitoring with promising potential for clinical application in sepsis patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.